Allison R. Schulman MD, MPH, FASGEAssociate Professor of Medicine and Surgery; Director of Bariatric Endoscopy, University of Michigan, Ann Arbor, Michigan
Allison Schulman, MD, MPH, is an Associate Professor in the Division of Gastroenterology and Hepatology and in the Department of General Surgery at University of Michigan. She received her bachelor's degree from Cornell University in Ithaca, New York, and her medical degree from Weill Cornell Medical College in New York City, where she was inducted into the Alpha Omega Alpha (AOA) Medical Honor Society. She received a Master’s in Public Health (MPH) at Harvard University. She completed her residency in Internal Medicine at the Brigham and Women's Hospital in Boston, MA. Following residency training, Dr. Schulman completed fellowship in Gastroenterology, and went on to complete two additional fellowships in Bariatric Endoscopy followed by Advanced/Therapeutic Endoscopy. All of her training was at Harvard/Brigham and Women's Hospital. She joined faculty at Michigan in 2017, and was appointed Director of Bariatric Endoscopy.
Dr. Schulman's research has focused on endoscopic management of obesity. She is specifically interested in management of complications following bariatric surgery, primary endoscopic therapy for obesity, and innovation and device development in endoscopy. She also has interests in interventional hepatology, and EUS/ERCP.
DisclosuresDr. Schulman reports the following:
- Apollo Endosurgery - Consultant
- Boston Scientific - Consultant
- Olympus – Consultant
- MicroTech – Consultant
- GI Dynamics - Research/Grant funding
Recent Contributions to PracticeUpdate:
- Endoscopic Sleeve Gastroplasty for Treating Patients With Class 1 and 2 Obesity
- Endoscopic Gastric Plication to Treat Weight Regain After Roux-en-Y Gastric Bypass
- Endoscopic vs Surgical Gastrojejunal Revision for Weight Regain in Roux-en-Y Gastric Bypass Patients
- Hydrothermal Duodenal Mucosal Resurfacing Safety and Efficacy in Patients With Type 2 Diabetes
- Duodenal Mucosal Resurfacing Combined With GLP-1RA to Discontinue Insulin in Type 2 Diabetes